2022 American Transplant Congress
Plasmapheresis and Rituximab for Prevention of Focal Segmental Glomerulosclerosis Recurrence Post-Kidney Transplantation
*Purpose: Primary focal segmental glomerulosclerosis (FSGS) recurs after kidney transplantation (KT) in 30-50% of recipients with a median time of 1.5 months post-KT. Recurrence is…2021 American Transplant Congress
Native Nephrectomy in Pediatric Kidney Transplant Recipients
*Purpose: Data on native nephrectomy in children with renal disease requiring kidney transplantation is scarce. The aim of this study was to characterize demographics and…2020 American Transplant Congress
Long-Term Outcomes for the Use of Native Small Capacity, Defunctionalized Bladders in Pediatric Kidney Transplantation
Stanford University Medical Center, Palo Alto, CA
*Purpose: Small capacity, defunctionalized urinary bladders present a challenge in pediatric kidney transplantation due to the inability to perform an adequate anti-reflux ureterocystostomy in a…2019 American Transplant Congress
Impact Of Rituximab And Maintenance Steroid In The Recurrence Of Focal Segmental Glomerulosclerosis
Transplant, Miami Transplant Institute-University of Miami, Miami, FL
*Purpose: Recurrence of focal segmental glomerulosclerosis (FSGS) has been reported between 20-80% with up to 60% of graft loss. Rituximab has demonstrated to be effective…2019 American Transplant Congress
Outcomes after Prolonged Therapeutic Plasma Exchange in Pediatric Kidney Transplant Patients with Early Recurrence of Focal Segmental Glomerular Sclerosis
*Purpose: Focal segmental glomerular sclerosis (FSGS) is the most common cause of glomerulonephritis leading to end-stage renal disease (ESRD) in pediatric patients. FSGS recurs frequently…2018 American Transplant Congress
FSGS Recurrence and Graft Survival in Pediatric Renal Transplants: A NAPRTCS Registry Analysis
IntroductionPrevious studies have raised concern of adverse outcome of living donor (LD) grafts in children transplanted for FSGS. This study reassesses impact of donor source,…2018 American Transplant Congress
Recurrence of Focal Segmental Glomerulosclerosis (FSGS) and Response to Prolonged Plasmapheresis Therapy: A Single Center Pediatric Experience
FSGS is the most common glomerular cause of ESKD in pediatric patients. The risk of recurrence after kidney transplant (KT) is 30-60%, and half of…2018 American Transplant Congress
Treatment Outcomes of FSGS Recurrence
Background: Recurrence of FSGS (focal segmental glomerulosclerosis) after kidney transplant occurs in 30% of adults and up to 80% of children and has impact on…2016 American Transplant Congress
Recurrence of FSGS Post Kidney Transplantation: Salvage Therapy with ACTHAR® Gel.
Transplant, Emory University, Atlanta, GA.
Recurrence of FSGS post kidney transplantation: Salvage therapy with ACTHAR® gel.Introduction:Recurrence of FSGS post kidney transplantation may reach 25-50%. Failure of treatment or incomplete remission…2016 American Transplant Congress
First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: There is extensive experience with rituximab (RTX,Type I anti-CD20) for desensitization (DES) and treatment of ABMR. There is also a comparable experience in treatment…
American Transplant Congress abstracts